MOVE Medacta Group

Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology Award from Orthopedics This Week

Medacta Group SA / Key word(s): Miscellaneous
Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology Award from Orthopedics This Week

24.09.2024 / 19:00 CET/CEST


MEDIA RELEASE

Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology Award from Orthopedics This Week

CASTEL SAN PIETRO, September 24, 2024—Medacta Group SA ("Medacta," SIX:MOVE) announced today its NextAR Rod Optimizer has been awarded the 2024 Spine Technology Award from Orthopedics This Week. This marks the third time a Medacta spine product has received this prestigious honor after the  Platform, patient-matched technology, and the , Augmented Reality Surgical Application.

The unique NextAR Rod Optimizer is a sustainable and personalized solution designed to enhance intraoperative planning and provide real-time selection starting from a dozen pre-bent rods that allow thousands of solutions1 in both minimally invasive and open approaches. Spine surgeons can now benefit from an advanced solution that eliminates the need for manual rod-bending, significantly reducing the risk of breakage and subsequent revision surgeries. This innovative approach also provides a compelling alternative to systems that are based on custom-made rods, eliminating preoperative imaging, production and waiting time, with significant advantages for surgeons and patients.

“NextAR Rod Optimizer provides the most accurate and easy to deploy point of care solution for selecting personalized rods for long fusion constructs, providing the optimal rod length and contour for percutaneous or open deformity constructs,” states Lionel Metz, MD, University of California San Francisco Department of Orthopedic Surgery.

The NextAR Rod Optimizer is part of NextAR Spine and may also be used as a stand-alone technology. This innovative tool complements Medacta's comprehensive spine offering by enhancing surgical procedures with cutting-edge precision and efficiency. NextAR Rod Optimizer aims to improve patient outcomes and streamline the surgical workflow. This advanced technology exemplifies Medacta's commitment to developing innovative and sustainable solutions that support both surgeons and patients.

The possibility of having an intraoperative planning tool to select a pre-bent rod among multiple solutions has enhanced my workflow and reduced potential complications associated with traditional techniques that require manual bending,” says Dr. Itsuo Shiina, from the Department of Orthopaedic Surgery, Moriya Daiichi Hospital, Japan.

The NextAR Rod Optimizer further expands the capabilities of the award-winning NextAR Spine, an innovative technology proven to be accurate in screw placement, and to seamlessly integrate into the OR workflow, enabling the surgeon to enhance efficiency, accuracy, and versatility in spine surgery2.

NextAR Spine is a sustainable solution within Medacta’s NextAR Augmented Reality Surgical Platform for both joint replacement and spine procedures. This hardware system offers the ability to host software for multiple applications (NextAR Knee, NextAR Shoulder, NextAR Spine). It is a vital component of the , a network of advanced digital solutions designed to enhance patient care and surgical outcomes.

The entire spine portfolio is supported by the comprehensive, tailored educational offerings provided by the . With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on spine procedures and products with personalized high-level educational pathways. With Medacta, the surgeon is never alone.

For more information about the NextAR Rod Optimizer, please visit .

 

Contact
Gianluca Olgiati
Group Vice President Marketing
0

 

Medacta is a key global player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 60 countries. Follow us on , , and .

 

RELATED TRADEMARKS
Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. MySolutions™ Personalized Ecosystem, NextAR™, NextAR™ Spine, NextAR™ Rod Optimizer, M.U.S.T.®.

REFERENCES
[1] Data on file Medacta

[2] Schwendner M, Ille S, Wostrack M, Meyer B. Evaluating a cutting-edge augmented reality-supported navigation system for spinal instrumentation. Eur Spine J. 2023 Nov 14. doi: 10.1007/s00586-023-08011-w. Epub ahead of print. PMID: 37962688.


Additional features:

File:


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1994629

 
End of News EQS News Service

1994629  24.09.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1994629&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
24/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medacta Group

Maria Vara ... (+3)
  • Maria Vara
  • Oscar Haffen Lamm
  • Valliant Campagne

Suspension of coverage

From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.INNATE PHARMAINVENTIVAMEDACTAMEDARTISONWARD MEDICALVALNEVA

Maria Vara
  • Maria Vara

Medacta: model update - Buy rating reiterated, unchanged CHF160 PT

We update our model following the publication of the company's annual report. No changes have been applied to our revenue forecast as FY 2024 results and 2025 guidance are aligned with our estimates. On the P&L, we have softened our S&M expenses expectation as these stood more towards 35.5%

 PRESS RELEASE

Medacta publishes 2025 Annual General Meeting invitation

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2025 Annual General Meeting invitation 08.04.2025 / 10:00 CET/CEST Press Release                     Medacta publishes 2025 Annual General Meeting invitation  CASTEL SAN PIETRO, 8 April 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Wednesday, 7 May 2025 at 11.00 a.m. at the Group premises in Via alla Rossa 6, Rancate, Switzerland. Shareholders can register to attend the Annual General Meeting in person but will also be abl...

Maria Vara
  • Maria Vara

Medacta: Exceptional FY2024 to fuel sustainable growth, adj. EBITDA hi...

Medacta reported preliminary unaudited FY 2024 revenue in early February; hence, the EUR590.6m figure was not a surprise. Nonetheless, we may highlight again that all four business lines delivered above the market growth with double-digit cc gains with a broad base geographical contribution. Gross

Maria Vara
  • Maria Vara

Medacta: expanding SportsMed footprint with Parcus Medical acquisition

Medacta expands its SportMeds footprint by acquiring Parcus Medical, a distinguished player with a diverse product family in sports medicine spanning the shoulder, knee, hip, and foot & ankle, with FY2024 unaudited revenues of USD16m. The acquisition not only expands Medacta's offering but also

ResearchPool Subscriptions

Get the most out of your insights

Get in touch